Influence of Fcγriia-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live-attenuated tetravalent dengue vaccine

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages 1-9

  Byers, Anthony M ^a   Broder, Ryan ^a   Haupfear, Kelly ^a   Timiryasova, Tatyana M ^a   Hu, Branda T ^a   Boaz, Mark ^a   Warren, William L ^a   Jackson, Nicholas ^a   Moser, Janice M ^a   Guy, Bruno ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Antibody; Dengue; Enhancement; Fc R; Vaccine

Indexed keywords

CD32 ANTIGEN; DENGUE VACCINE; FC RECEPTOR IIA; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONCENTRATION (PARAMETERS); DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; SEROTYPE; VACCINATION;

EID: 85014117666     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv172     Document Type: Article

References (38)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310-2.
3. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008; 82:6631-43.
4. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81.
5. Midgley CM, Bajwa-Joseph M, Vasanawathana S, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85:410-21.
6. Guzman MG, Kouri GP, Bravo J, et al. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
7. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 1973; 128:15-22.
8. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010; 338:83-98.
9. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120:653-69.
10. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265:739-41.
11. Kliks SC, Nisalak A, Brandt WE, et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
12. Morens DM, Halstead SB. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 1990; 71:2909-14.
13. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65.
14. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23.
15. Baldinotti F, Matteucci D, Mazzetti P, et al. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol 1994; 68:4572-9.
16. Mann AM, Rusert P, Berlinger L, et al. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 2009; 23:1659-67.
17. Mannini-Palenzona A,Moschella A, Costanzo F, et al. Cell-type dependent sensitivity of herpes simplex virus 1 mutants to plaque development inhibition by an anti-gDmonoclonal antibody. NewMicrobiol 1995; 18:351-8.
18. Mukherjee S, Dowd KA, Manhart CJ, et al. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol 2014; 88:7210-20.
19. Oliphant T, Nybakken GE, Engle M, et al. Antibody recognition and neutralization determinants on domains I and II ofWest Nile Virus envelope protein. J Virol 2006; 80:12149-59.
20. ZhaiW, Zhang DN, Mai C, et al. Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies. PLoS One 2012; 7:e52327.
21. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
22. Boonnak K, Slike BM, Donofrio GC, Marovich MA. Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 2013; 190:5659-65.
23. Chan KR, Zhang SL, Tan HC, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 2011; 108:12479-84.
24. Rodrigo WW, Block OK, Lane C, et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 2009; 394:175-82.
25. Wu RS, Chan KR, Tan HC, et al. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotypespecific from cross-neutralizing antibodies. Antiviral Res 2012; 96:340-3.
26. Williams KL, Sukupolvi-Petty S, Beltramello M, et al. Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog 2013; 9:e1003157.
27. Boonnak K, Slike BM, Burgess TH, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008; 82:3939-51.
28. Rodrigo WW, Jin X, Blackley SD, et al. Differential enhancement of dengue virus immune complex infectivity mediated by signalingcompetent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006; 80:10128-38.
29. Rodrigo WW, Alcena DC, Kou Z, et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol 2009; 16:285-7.
30. Rodrigo WW, Alcena DC, Rose RC, et al. An automated Dengue virus microneutralization plaque assay performed in human Fc(gamma) receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009; 80:61-5.
31. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
32. Torresi J, Heron LG, Qiao M, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine 2015; 33:5127-34.
33. Dayan GH, Garbes P, Noriega F, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013; 89:1058-65.
34. Timiryasova TM, Bonaparte MI, Luo P, et al. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013; 88:962-70.
35. Guy B, Chanthavanich P, Gimenez S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563-74.
36. van Panhuis WG, Gibbons RV, Endy TP, et al. Inferring the serotype associated with dengue virus infections on the basis of pre-and postinfection neutralizing antibody titers. J Infect Dis 2010; 202:1002-10.
37. Puschnik A, Lau L, Cromwell EA, et al. Correlation between denguespecific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 2013; 7:e2274.
38. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.